References
- Rybak LP, Whitworth CA, Mukherjea D, et al. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res. 2007;226:157–167.
- Gika HG, Theodoridis GA, Plumb RS, et al. Current practice of liquid chromatography-mass spectrometry in metabolomics and metabonomics. J Pharm Biomed Anal. 2014;87:12–25.
- Galluzzi L, Vitale I, Michels J, et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis. 2014;5:e1257.
- Laurell G, Ekborn A, Viberg A, et al. Effects of a single high dose of cisplatin on the melanocytes of the stria vascularis in the guinea pig. Audiol Neurootol. 2007;12:170–178.
- Engskog MK, Ersson L, Haglof J, et al. beta-N-Methylamino-L-alanine (BMAA) perturbs alanine, aspartate and glutamate metabolism pathways in human neuroblastoma cells as determined by metabolic profiling. Amino Acids. 2017;49:905–919.
- Trygg J, Holmes E, Lundstedt T. Chemometrics in metabonomics. J Proteome Res. 2007;6:469–479.
- Freyer DR, Chen L, Krailo MD, et al. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18:63–74.
- Riedl S, Zweytick D, Lohner K. Membrane-active host defense peptides-challenges and perspectives for the development of novel anticancer drugs. Chem Phys Lipids. 2011;164:766–781.
- Schauer R. Achievements and challenges of sialic acid research. Glycoconj J. 2000;17:485–499.
- Sillanaukee P, Ponnio M, Jaaskelainen IP. Occurrence of sialic acids in healthy humans and different disorders. Eur J Clin Invest. 1999;29:413–425.
- Kart A, Yapar K, Karapehlivan M, et al. Effects of L-carnitine on kidney histopathology, plasma and tissue total sialic acid, malondialdehyde and glutathione concentrations in response to gentamicin administration in Balb/C mice. Revue Méd Vét. 2006;157:179–184.
- de Groot JC, Hendriksen EG, Smoorenburg GF. Reduced expression of sialoglycoconjugates in the outer hair cell glycocalyx after systemic aminoglycoside administration. Hear Res. 2005;205:68–82.
- Onofrj M, Ciccocioppo F, Varanese S, et al. Acetyl-L-carnitine: from a biological curiosity to a drug for the peripheral nervous system and beyond. Expert Rev Neurother. 2013;13:925–936.
- Haschke M, Vitins T, Lude S, et al. Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs. Nephrol Dial Transplant. 2010;25:426–433.
- Devarajan P, Savoca M, Castaneda MP, et al. Cisplatin-induced apoptosis in auditory cells: role of death receptor and mitochondrial pathways. Hear Res. 2002;174:45–54.
- Yang Y, Liu H, Liu F, et al. Mitochondrial dysregulation and protection in cisplatin nephrotoxicity. Arch Toxicol. 2014;88:1249–1256.
- Gunes D, Kirkim G, Kolatan E, et al. Evaluation of the effect of acetyl L-carnitine on experimental cisplatin ototoxicity and neurotoxicity. Chemotherapy. 2011;57:186–194.
- Galadari S, Rahman A, Pallichankandy S, et al. Tumor suppressive functions of ceramide: evidence and mechanisms. Apoptosis. 2015;20:689–711.
- Roh JL, Park JY, Kim EH, et al. Targeting acid ceramidase sensitises head and neck cancer to cisplatin. Eur J Cancer. 2016;52:163–172.
- Tani K, Tabuchi K, Hara A. Hair cell loss induced by sphingosine and a sphingosine kinase inhibitor in the rat cochlea. Neurotox Res. 2016;29:35–46.